Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Comprehensive Study Of The Clinical Phenotype Of Germline BAP1 Variant-Carrying Families Worldwide
S. Walpole, A. Pritchard, C. Cebulla, R. Pilarski, Meredith Stautberg, F. Davidorf, A. de la Fouchardière, O. Cabaret, L. Golmard, D. Stoppa-Lyonnet, E. Garfield, C. Njauw, M. Cheung, J. Turunen, P. Repo, Reetta-Stiina Järvinen, R. van Doorn, M. Jager, Gregorius P M Luyten, M. Marinkovic, Cindy Chau, M. Potrony, V. Höiom, H. Helgadottir, L. Pastorino, W. Bruno, V. Andreotti, B. Dalmasso, G. Ciccarese, P. Queirolo, L. Mastracci, K. Wadt, J. Kiilgaard, M. Speicher, Natasha M van Poppelen, E. Kiliç, Rana'a T. Al-Jamal, I. Dianzani, M. Betti, C. Bergmann, S. Santagata, S. Dahiya, S. Taibjee, J. Burke, N. Poplawski, S. O'Shea, J. Newton-Bishop, J. Adlard, D. Adams, Anne-Marie Lane, I. Kim, S. Klebe, H. Racher, J. Harbour, M. Nickerson, R. Murali, J. Palmer, Madeleine Howlie, J. Symmons, H. Hamilton, Sunil K. Warrier, W. Glasson, P. Johansson, C. D. Robles-Espinoza, Raul Ossio, A. de Klein, S. Puig, P. Ghiorzo, M. Nielsen, T. Kivelä, H. Tsao, J. Testa, Pedram Gerami, M. Stern, B. B. Paillerets, M. Abdel-Rahman, N. Hayward
Published 2018 · Biology, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Background The BRCA1-associated protein-1 (BAP1) tumor predisposition syndrome (BAP1-TPDS) is a hereditary tumor syndrome caused by germline pathogenic variants in BAP1 encoding a tumor suppressor associated with uveal melanoma, mesothelioma, cutaneous melanoma, renal cell carcinoma, and cutaneous BAP1-inactivated melanocytic tumors. However, the full spectrum of tumors associated with the syndrome is yet to be determined. Improved understanding of the BAP1-TPDS is crucial for appropriate clinical management of BAP1 germline variant carriers and their families, including genetic counseling and surveillance for new tumors. Methods We collated germline variant status, tumor diagnoses, and information on BAP1 immunohistochemistry or loss of somatic heterozygosity on 106 published and 75 unpublished BAP1 germline variant-positive families worldwide to better characterize the genotypes and phenotypes associated with the BAP1-TPDS. Tumor spectrum and ages of onset were compared between missense and null variants. All statistical tests were two-sided. Results The 181 families carried 140 unique BAP1 germline variants. The collated data confirmed the core tumor spectrum associated with the BAP1-TPDS and showed that some families carrying missense variants can exhibit this phenotype. A variety of noncore BAP1-TPDS -associated tumors were found in families of variant carriers. Median ages of onset of core tumor types were lower in null than missense variant carriers for all tumors combined (P < .001), mesothelioma (P < .001), cutaneous melanoma (P < .001), and nonmelanoma skin cancer (P < .001). Conclusions This analysis substantially increases the number of pathogenic BAP1 germline variants and refines the phenotype. It highlights the need for a curated registry of germline variant carriers for proper assessment of the clinical phenotype of the BAP1-TPDS and pathogenicity of new variants, thus guiding management of patients and informing areas requiring further research.
This paper references
Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction.
M. Cheung (2015)
Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma
N. Farquhar (2018)
Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?
E. Pulford (2017)
Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas
G. Shankar (2017)
Analysis of the exome aggregation consortium (ExAC) database suggests that the BAP1‐tumor predisposition syndrome is underreported in cancer patients
James B. Massengill (2018)
BAP1 is phosphorylated at serine 592 in S‐phase following DNA damage
Ziad M Eletr (2013)
Germline BAP1 mutations predispose also to multiple basal cell carcinomas
A. de la Fouchardière (2015)
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
T. Milman (2011)
BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression
D. Jensen (1998)
A Novel Germline Mutation in BAP1 Predisposes to Familial Clear-Cell Renal Cell Carcinoma
Megan N Farley (2013)
BAP1 Tumor Predisposition Syndrome
R. Pilarski (2016)
Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases
K. Rai (2016)
Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma
L. Gossage (2014)
Ocular melanoma: an overview of the current status.
P. Jovanovic (2013)
Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise
Supriya K. Saha (2016)
Germline mutations in BAP1 impair its function in DNA double-strand break repair.
I. H. Ismail (2014)
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.
Q. Ostrom (2014)
A novel BAP1 mutation is associated with melanocytic neoplasms and thyroid cancer.
Kevin J. McDonnell (2016)
Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair
Helen Yu (2013)
Inactivation of BAP 1 / ASXL 2 DUB activity in cancer 1 The BAP 1 / ASXL 2 Histone H 2 A Deubiquitinase Complex Regulates Cell Proliferation and is Disrupted in Cancer *
Salima Daou (2015)
Germline BAP1 mutations predispose to renal cell carcinomas.
Tatiana Popova (2013)
Surveillance Epidemology and End Results Program ( SEER )
NA HowladerN (1996)
BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization.
Karen H. Ventii (2008)
CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014
Q. Ostrom (2017)
Primary peritoneal mesothelioma: case series and literature review.
H. Sharma (2011)
A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma
K.A.W. Wadt (2015)
Molecular architecture of polycomb repressive complexes
Emily C. Chittock (2017)
Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.
Jinfei Xu (2014)
Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s
M. Carbone (2015)
NeuCode Proteomics Reveals Bap1 Regulation of Metabolism.
Joshua M. Baughman (2016)
BRCA-associated protein 1 mutant cholangiocarcinoma: an aggressive disease subtype.
Humaid Al-Shamsi (2016)
Germline BAP1 Inactivation Is Preferentially Associated with Metastatic Ocular Melanoma and Cutaneous-Ocular Melanoma Families
C. Njauw (2012)
Evaluating the clinical validity of gene-disease associations: an evidence-based framework developed by the Clinical Genome Resource
Natasha T Strande (2017)
Germline BAP1-positive patients: the dilemmas of cancer surveillance and a proposed interdisciplinary consensus monitoring strategy.
P. Star (2018)
Deubiquitination of γ-tubulin by BAP1 prevents chromosome instability in breast cancer cells.
Reihaneh Zarrizi (2014)
Bap1 Is a Bona Fide Tumor Suppressor: Genetic Evidence from Mouse Models Carrying Heterozygous Germline Bap1 Mutations.
Yuwaraj Kadariya (2016)
Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers
M. Abdel-Rahman (2011)
The Ubiquitin Carboxyl Hydrolase BAP1 Forms a Ternary Complex with YY1 and HCF-1 and Is a Critical Regulator of Gene Expression
Helen Yu (2010)
Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases
R. Pilarski (2014)
BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation
A. Bononi (2017)
UMD‐Predictor: A High‐Throughput Sequencing Compliant System for Pathogenicity Prediction of any Human cDNA Substitution
David Salgado (2016)
Familial and Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains.
H. Peng (2018)
Occurrence of BAP1 germline mutations in cutaneous melanocytic tumors with loss of BAP1‐expression: A pilot study
O. Cabaret (2017)
Well-differentiated papillary mesothelioma: clustering in a Portuguese family with a germline BAP1 mutation.
C. Ribeiro (2013)
Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.
J. Ohar (2016)
Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment
G. Gezgin (2017)
BAP1 Germline Mutations in Finnish Patients with Uveal Melanoma.
J. Turunen (2016)
Web-TCGA: an online platform for integrated analysis of molecular cancer data sets
Mario Deng (2016)
Primary leptomeningeal melanoma is part of the BAP1-related cancer syndrome
A. Fouchardière (2015)
Germline BAP1 mutations predispose to malignant mesothelioma
J. Testa (2011)
ERRATUM: Blood ammonia and glutamine as predictors of hyperammonemic crises in patients with urea cycle disorder
Concurrent Alterations in TERT, KDM6A, and the BRCA Pathway in Bladder Cancer
M. Nickerson (2014)
Prognostic significance of BRCA1-associated protein 1 in colorectal cancer
Jianjun Tang (2013)
BAP1 Protein is a Progression Factor in Malignant Pleural Mesothelioma
L. Arzt (2013)
Germline BAP1 mutations induce a Warburg effect
A. Bononi (2017)
Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.
F. Baumann (2015)
Germline mutations in BAP1 predispose to melanocytic tumors
T. Wiesner (2011)
The forkhead transcription factor FOXK2 acts as a chromatin targeting factor for the BAP1-containing histone deubiquitinase complex
Zongling Ji (2014)
COSMIC: somatic cancer genetics at high-resolution
S. Forbes (2017)
Incidence trends and gender differences in malignant mesothelioma in New South Wales, Australia.
Rebecca A Hyland (2007)
Performance of in silico prediction tools for the classification of rare BRCA1/2 missense variants in clinical diagnostics
C. Ernst (2018)
Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature
A. Haugh (2017)
Cancer associated missense mutations in BAP1 catalytic domain induce amyloidogenic aggregation: A new insight in enzymatic inactivation
S. Bhattacharya (2015)
Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma
A. Napolitano (2016)
Systematic Analysis of Splice-Site-Creating Mutations in Cancer
R. Jayasinghe (2018)
ClinVar: improving access to variant interpretations and supporting evidence
M. Landrum (2018)
The BAP1/ASXL2 Histone H2A Deubiquitinase Complex Regulates Cell Proliferation and Is Disrupted in Cancer*♦
Salima Daou (2015)
Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network
A. Hakimi (2013)
Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation.
P. Kapur (2013)
Germline BAP1 mutations also predispose to cutaneous squamous cell carcinoma.
R. Rawson (2017)
Tissue-specific significance of BAP1 gene mutation in prognostic prediction and molecular taxonomy among different types of cancer
Xiang-yu Wang (2017)
This paper is referenced by
The Separation of Benign and Malignant Mesothelial Proliferations
A. Churg (2020)
Loss of BAP1 in Pheochromocytomas and Paragangliomas Seems Unrelated to Genetic Mutations
Valeria Maffeis (2019)
BAP1-Mutated Clear Cell Renal Cell Carcinoma.
A. Gallan (2020)
Thirty-six-year-old woman with a liver mass: diagnosis hidden in history
S. Vos (2020)
Preclinical Models of Malignant Mesothelioma
J. Testa (2020)
An adolescent with uveal melanoma and BAP1 tumor predisposition syndrome
Kelly Z. Young (2020)
Intraocular Metastasis in Unilateral Multifocal Uveal Melanoma Without Melanocytosis or Germline BAP1 Mutations.
M. Durante (2019)
Concurrent germline and somatic pathogenic BAP1 variants in a patient with metastatic bladder cancer
Megan E. Tesch (2020)
Loss of BAP1 Leads to More YAPing in Pancreatic Cancer
R. Brekken (2020)
Brief Report: Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations.
M. Zauderer (2019)
Loss-of-function variants in POT1 predispose to uveal melanoma.
Vaishnavi Nathan (2020)
Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival
Lisa Quetel (2020)
Emerging Drug Therapies for Mesothelioma
D. B. Oien (2020)
Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1
L. Pastorino (2020)
Uveal Melanoma in BAP1 Tumor Predisposition Syndrome: Estimation of Risk.
Nakul Singh (2020)
BAP1 Tumour Predisposition Syndrome: A New Mutation in One Family.
F. Satolli (2019)
Iris Colour and the Risk of Developing Uveal Melanoma
Laurien E Houtzagers (2020)
BAP1 tumor predisposition syndrome case report: pathological and clinical aspects of BAP1-inactivated melanocytic tumors (BIMTs), including dermoscopy and confocal microscopy
Bianca Costa Soares de Sá (2019)
Tumour predisposition and cancer syndromes as models to study gene–environment interactions
M. Carbone (2020)
GENOTYPE – PHENOTYPE CORRELATIONS IN CUTANEOUS MELANOMA PATIENTS CARRIER OF THE MITF p . E 318 K PATHOGENIC VARIANT
A. Szent-Gyorgyi (2019)
Les cancers du rein héréditaires vus par le pathologiste en 2020
V. Verkarre (2020)
Mesothelioma developing in carriers of inherited genetic mutations.
Yoshie Yoshikawa (2020)
Genetic Alterations in Renal Cancers: Identification of The Mechanisms Underlying Cancer Initiation and Progression and of Therapeutic Targets
U. Testa (2020)
How asbestos and other fibers cause mesothelioma.
G. Gaudino (2020)
Functional characterisation guides classification of novel BAP1 germline variants
J. H. Hong (2020)
Germline MBD4 Mutations and Predisposition to Uveal Melanoma
Anne-Céline Derrien (2020)
Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights.
Maria I Carlo (2019)
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
M. Carbone (2019)
BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers
Jeffim N. Kuznetsov (2019)
Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG)
M. Li (2020)
Genetic predisposition for malignant mesothelioma: A concise review.
M. Betti (2019)
The Molecular Basis of Malignant Pleural Mesothelioma.
Benjamin Wadowski (2020)See more